Marisa Wexler, MS,  senior science writer—

Therapeutic plasma exchange may help ease digestive issues in people with limited systemic scleroderma (lcSSc), new research indicates. Edward Harris of the Scleroderma Education Project presented the findings at the American Society for Apheresis (ASFA) annual meeting in Philadelphia earlier this month, in a poster titled, “The Effects…

Among people with systemic scleroderma (SSc), those who have digital ulcers (DUs) — sores on their fingers or toes — tend to use more healthcare resources, a new study suggests. “Our study demonstrates increased health resource utilization by SSc patients with DUs compared to those without DUs in a…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Treatment with stem cells grown into a skin-like structure called an organoid reduced inflammation and fibrosis (scarring) in a mouse model of localized scleroderma, a new study found. The study, “Application of an iPSC-Derived Organoid Model for Localized Scleroderma Therapy,” was published in Advanced Science.

Two medications — one for arthritis and the other for diabetes — were able to lessen scarring and inflammation in a mouse model of systemic scleroderma (SSc), according to a new study. These results support further research into the medications, tofacitinib and metformin, and others that target the JAK/STAT…

Levels of signaling molecules called cytokines can be used to identify people with systemic scleroderma (SSc) who are at highest risk of developing abnormally high blood pressure in their lungs, a new study reports. The study, “Cytokine signatures differentiate systemic sclerosis patients at high versus low…

Acazicolcept (ALPN-101), an experimental therapy that blocks T-cell activation and is being developed by Alpine Immune Sciences, was found effective at decreasing scarring in mouse models of systemic sclerosis (SSc). A team of scientists at Alpine and other institutions published their findings in a study, “…

Among people with systemic scleroderma, education and income are major determinants of perceived functional ability, a new study indicates. Findings also point to skin involvement and age as substantial determinants of functionality. “These results may serve to give clinicians novel insight into the predictive factors of patient function and…

Prometheus Biosciences is planning a clinical trial of its investigational anti-inflammatory and antifibrotic medication PRA023 in people with systemic scleroderma-associated interstitial lung disease (SSc-ILD), a form of scleroderma characterized by inflammation and scarring (fibrosis) in the lungs. The Phase 2 study, called ATHENA-SSc-ILD, is planned to launch early…

Scleroderma renal crisis (SRC), a rare and severe manifestation of systemic scleroderma, is disproportionately common in Blacks, a new study reports. “Black race was independently associated with a higher risk of future SRC,” its researchers wrote. “Further studies are needed to elucidate the mechanisms that underlie this important association.”…